Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Lynskey

Vascular & Interventional Radiology Oxon Hill, MD Medical Doctor

NPI 1336391416 CMS profile 913729

174 Waterfront St Ste 320, Oxon Hill, MD 20745

Open in the dashboard

General payments

$22,234

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Lynskey of Oxon Hill, MD is reported in the CMS Open Payments database as having received $22,234 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,259 13
2024 General $337 12
2023 General $13,082 17
2022 General $407 17
2021 General $896 8
2020 General $819 11
2019 General $434 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Lynskey
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to George Lynskey were reported at $6,259. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year George Lynskey Vascular & Interventional Radiology median Middle half National median
2019 $434 $422 $125–$1,555 $163
2020 $819 $200 $68–$652 $114
2021 $896 $280 $99–$866 $132
2022 $407 $433 $137–$1,497 $149
2023 $13,082 $506 $152–$2,019 $160
2024 $337 $556 $175–$1,930 $164
2025 $6,259 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Siemens Medical Solutions USA, Inc. $13,026 15 payments
  2. Sirtex Medical Inc $6,460 10 payments
  3. W. L. Gore & Associates, Inc. $740 2 payments
  4. Boston Scientific Corporation $497 18 payments
  5. AngioDynamics, Inc. $239 2 payments
  6. Inari Medical, Inc. $176 3 payments
  7. Stryker Corporation $175 1 payment
  8. Abbott Laboratories $167 3 payments
  9. Surefire Medical, Inc. $137 3 payments
  10. Tactile Systems Technology Inc $127 6 payments
  11. Other $488 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $12,425 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 2 payments
  3. Food and Beverage $2,776 75 payments
  4. Travel and Lodging $1,033 4 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $6,460 10 payments
  2. Product in Development $740 2 payments
  3. SPINEJACK $175 1 payment
  4. Precision Infusion System $137 3 payments
  5. Flexitouch Plus $127 6 payments
  6. FlowTriever $122 2 payments
  7. ClotTriever $122 2 payments
  8. AMPLATZER Vascular Plug and Accs $117 1 payment
  9. General - Vascular Intervention $112 4 payments
  10. GATTEX $110 6 payments
  11. Other $1,182 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

34

Prescriptions dispensed, refills included

Drug cost

$309

Paid at the pharmacy, in all

Branded share of claims

100%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 34 $309

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$559,646

Of which drugs: $136

Medicare patients

164

Average age 75

Services billed

2,166

89 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 54%
Chronic kidney disease 51%
Ischemic heart disease 40%
Heart failure 27%
Atrial fibrillation 24%
Cancer 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 24 878 $90
Injection, fentanyl citrate, 0.1 mg J3010 Office 29 46 $35
Injection, midazolam hydrochloride, per 1 mg J2250 Office 36 108 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record